WHO publishes European Regional Office report
This article was originally published in Scrip
Executive Summary
The World Health Organization has published The Work of the WHO in the European Region, 2006-2007, a report examining the work of the WHO regional office for Europe over the past two years. The publication covers the regional office's actions to offer country-specific services on health policy and health systems, including work to improve and strengthen these systems; work done from both normative and technical perspectives; and structure, resources and governance used by the office. There is also an annex of the programme budget and consideration of cross-cutting issues, including partnerships and health intelligence. The report is free of charge and can be ordered or downloaded from http://www.euro.who.int/.
You may also be interested in...
How to leverage India: Five up-and-coming domestic players
The Indian pharmaceutical sector is recognised for its entrepreneurial spirit. Many companies have crafted successful business strategies by offering API manufacturing, drug discovery, CRAMS and other services to global pharmaceutical customers. Others market their products overseas while leveraging growth opportunities on their home turf. The following five domestic companies are well worth watching in 2011.
Active Biotech appoints CSO
The Swedish biotech firm Active Biotech has appointed Dr Helén Tuvesson as its new chief scientific officer, effective 1 April. Dr Tuvesson has been with the company since 1998, working in preclinical development, R&D management and most recently within the senior management team. She will report to president and CEO Tomas Leanderson.
Affimed appoints new chief commercial officer
Affimed Therapeutics (Germany) has appointed Dr Adi Hoess as its new chief commercial officer. Effective immediately, Mr Hoess will focus on commercial and strategic management and business development, complimenting his previous senior management and business development roles at Jenowis, Carl Zeiss Jena, MorphoSys and Jerini. His appointment also coincides with the continued development of the company's lead product candidate, AFM13, for Hodgkin's lymphoma, which entered a Phase I clinical trial last November (scripintelligence.com, 15 November 2010).